The acquisition of Inversago includes the company's lead development asset INV-202, an oral CB1 inverse agonist. INV-202 is designed to preferentially block the ...

10 авг. 2023 г. · Danish drug maker Novo Nordisk said on Thursday it would acquire Canadian company Inversago Pharma in a $1.07 billion deal including the ...

10 авг. 2023 г. · Acquisition by Novo Nordisk for up to USD 1.075 billion in cash pending milestones • Inversago Pharma is a clinical stage company developing ...

10 авг. 2023 г. · Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases.

10 авг. 2023 г. · Novo Nordisk on Thursday said it will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion to broaden the ...

10 авг. 2023 г. · Amongst fierce competition in the obesity space, Novo Nordisk has spent $1bn to acquire Inversago Pharma to shore up its weight loss treatment ...

10 авг. 2023 г. · Novo Nordisk agreed to buy metabolic disorder specialist Inversago Pharma in a deal worth as much as about $1.1 billion as the Danish company ...

10 авг. 2023 г. · Novo Nordisk A/S has agreed to acquire Inversago ... Through the acquisition agreement, the pharma company Novo Nordisk intends to investigate ...

10 авг. 2023 г. · The acquisition agreement comes amid record sales of Novo's weight-loss drug Wegovy (semaglutide), which during the second quarter earned over ...

10 авг. 2023 г. · Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1.